R
Rasmus Bo Hasselbalch
Researcher at Copenhagen University Hospital
Publications - 48
Citations - 1089
Rasmus Bo Hasselbalch is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 26 publications receiving 487 citations. Previous affiliations of Rasmus Bo Hasselbalch include Herlev Hospital & Gentofte Hospital.
Papers
More filters
Journal ArticleDOI
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study.
Kasper Iversen,Henning Bundgaard,Rasmus Bo Hasselbalch,Jonas H Kristensen,Pernille B Nielsen,Mia Pries-Heje,Andreas Knudsen,Casper Emil Christensen,Kamille Fogh,Jakob B Norsk,Ove Andersen,Thea Kølsen Fischer,Claus J. Jensen,Margit Hørup Larsen,Christian Torp-Pedersen,Jørgen Rungby,Sisse B. Ditlev,Ida Hageman,Rasmus Mogelvang,Christoffer Hother,Mikkel Gybel-Brask,Erik Sørensen,Lene Holm Harritshøj,Fredrik Folke,Curt Sten,Thomas Benfield,Susanne Dam Nielsen,Henrik Ullum +27 more
TL;DR: The prevalence of antibodies against SARS-CoV-2 in health-care workers and the proportion of seroconverted health-Care workers with previous symptoms of COVID-19 were investigated and found to be significantly higher than in blood donors.
Journal ArticleDOI
Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial.
Henning Bundgaard,Johan S Bundgaard,Daniel Emil Tadeusz Raaschou-Pedersen,Christian von Buchwald,Tobias Todsen,Jakob B Norsk,Mia Pries-Heje,Christoffer Rasmus Vissing,Pernille B Nielsen,Ulrik C Winsløw,Kamille Fogh,Rasmus Bo Hasselbalch,Jonas H Kristensen,Anna Ringgaard,Mikkel Porsborg Andersen,Nicole Bakkegård Goecke,Ramona Trebbien,Kerstin Skovgaard,Thomas Benfield,Henrik Ullum,Christian Torp-Pedersen,Kasper Iversen +21 more
TL;DR: This randomized controlled trial investigates whether recommending surgical mask use when outside the home reduces wearers' risk for SARS-CoV-2 infection in a setting where masks were uncommon and not among recommended public health measures.
Journal ArticleDOI
Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories.
Lene Holm Harritshøj,Mikkel Gybel-Brask,Shoaib Afzal,Shoaib Afzal,Pia R. Kamstrup,Charlotte Sværke Jørgensen,Marianne Kragh Thomsen,Linda Hilsted,Lennart Friis-Hansen,Pal B. Szecsi,Lise Pedersen,Lene Nielsen,Cecilie Bo Hansen,Peter Garred,Peter Garred,Trine-Line Korsholm,Susan Mikkelsen,Kirstine O. Nielsen,Bjarne Kuno Møller,Anne Tybjaerg Hansen,Kasper Iversen,Pernille B Nielsen,Rasmus Bo Hasselbalch,Kamille Fogh,Jakob B Norsk,Jonas H Kristensen,Kristian Schønning,Nikolai Kirkby,Alex C. Y. Nielsen,Lone H. Landsy,Mette Loftager,Dorte Kinggaard Holm,Anna Christine Nilsson,Susanne Gjørup Sækmose,Birgitte Grum-Schwensen,Bitten Aagaard,Thøger Gorm Jensen,Thøger Gorm Jensen,Dorte M. Nielsen,Henrik Ullum,Henrik Ullum,Henrik Ullum,Ram Benny Dessau +42 more
TL;DR: In this paper, the authors evaluated 15 commercial and one in-house anti-SARS-CoV-2 assays in 16 laboratories and achieved a specificity of ≥ 99% for all total-Ab and IgG assays except one, DiaSorin Liaison XL IgG (97.2%).
Journal ArticleDOI
Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
Laura Pérez-Alós,Jose Juan Almagro Armenteros,Johannes R. Madsen,Cecilie Bo Hansen,Ida Jarlhelt,Sebastian Rask Hamm,Line Dam Heftdal,Mia Pries-Heje,Dina Leth Møller,Kamille Fogh,Rasmus Bo Hasselbalch,Anne Rosbjerg,Søren Brunak,E. Sørensen,Margit Hørup Larsen,Sisse R. Ostrowski,Ruth Frikke-Schmidt,Rafael Bayarri-Olmos,Linda Hilsted,Kasper Iversen,Henning Bundgaard,Susanne Dam Nielsen,Peter Garred +22 more
TL;DR: In this paper , the authors examined antibody levels and T-cell gamma-interferon release after two doses of BNT162b2 vaccine or a combination of ChAdOx1-nCoV19 and BNT 162b2 vaccines for up to 230 days after the first dose.
Journal ArticleDOI
The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial.
Henning Bundgaard,Anna Axelsson,J. H. Thomsen,Mathias Sørgaard,Klaus F. Kofoed,Rasmus Bo Hasselbalch,N. Fry,Nana Valeur,Søren Boesgaard,Finn Gustafsson,Lars Køber,Kasper Iversen,Helge H. Rasmussen +12 more
TL;DR: The third isotype of beta adrenergic receptors (β3 ARs) has distinctly different effects on cardiomyocytes compared with β1 and β2 ARs and treatment with the β3 AR agonist mirabegron increases LVEF in patients with HF.